Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

SRI International awarded $40m to develop contraceptive products

Posted: 28 October 2015 | Victoria White

Under the contract, SRI International will conduct all research and testing necessary to submit Investigational New Drug applications for promising drugs…

SRI International has been awarded a Biological Testing Facility (BTF) contract of up to $40 million from the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD) to conduct preclinical development of potential new contraceptive and therapeutic products.

Under the contract, SRI Biosciences, a division of SRI International, will conduct all research and testing necessary to submit Investigational New Drug (IND) applications for promising drugs and devices.

NICHD conducts and supports laboratory research, clinical trials, and epidemiological studies that explore health processes; examines the impact of disabilities, diseases, and variations on the lives of individuals; and sponsors training programs to ensure that NICHD research can continue. The NICHD’s BTF funds research to move contraceptive targets into development and, as appropriate, approval.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

SRI International will support the development of contraceptive products over the next five years

“We are pleased to continue supporting this important research on behalf of NICHD, which requires both state-of-the-art facilities and a broad range of preclinical research capabilities,” said Toufan Parman, Ph.D., D.A.B.T, director, General Toxicology, SRI Biosciences, and principal investigator for the NICHD contract.

Over the next five years, SRI will be responsible for providing all support services necessary to advance high quality, safe, effective male and female contraceptive products to human clinical trials.

Related topics

Related organisations